|64.33||-0.2600||-0.40%||Vol 426.28K||1Y Perf 13.90%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||0.43 0.67%|
|Target Price||64.89||Analyst Rating||Strong Buy 1.30|
|Potential %||0.87||Finscreener Ranking||★+ 44.44|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★ 39.74|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 49.58|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★ 33.14|
|Price Range Ratio 52W %||63.02||Earnings Rating||Neutral|
|Market Cap||6.45B||Earnings Date||26th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.77|
|EPS Growth Next 5 Years %||13.50|
|Avg. Weekly Volume||318.11K|
|Avg. Monthly Volume||576.48K|
|Avg. Quarterly Volume||592.85K|
Encompass Health Corporation (NYSE: EHC) stock closed at 64.59 per share at the end of the most recent trading day (a -0.83% change compared to the prior day closing price) with a volume of 324.15K shares and market capitalization of 6.45B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 43178 people. Encompass Health Corporation CEO is Mark J. Tarr.
The one-year performance of Encompass Health Corporation stock is 13.9%, while year-to-date (YTD) performance is 7.99%. EHC stock has a five-year performance of -12.88%. Its 52-week range is between 51.15 and 72.0631, which gives EHC stock a 52-week price range ratio of 63.02%
Encompass Health Corporation currently has a PE ratio of 22.60, a price-to-book (PB) ratio of 5.04, a price-to-sale (PS) ratio of 1.88, a price to cashflow ratio of 9.40, a PEG ratio of 1.67, a ROA of 4.86%, a ROC of 8.65% and a ROE of 19.54%. The company’s profit margin is 7.74%, its EBITDA margin is 19.00%, and its revenue ttm is $3.21 Billion , which makes it $32.18 revenue per share.
Of the last four earnings reports from Encompass Health Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.77 for the next earnings report. Encompass Health Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Encompass Health Corporation is Strong Buy (1.3), with a target price of $64.89, which is +0.87% compared to the current price. The earnings rating for Encompass Health Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Encompass Health Corporation has a dividend yield of 0.99% with a dividend per share of $0.60 and a payout ratio of 29.00%.
Encompass Health Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.72, ATR14 : 1.17, CCI20 : 54.17, Chaikin Money Flow : 0.04, MACD : 0.27, Money Flow Index : 50.30, ROC : 0.84, RSI : 50.93, STOCH (14,3) : 53.53, STOCH RSI : 0.00, UO : 53.15, Williams %R : -46.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Encompass Health Corporation in the last 12-months were: Coltharp Douglas (Option Excercise at a value of $800 493), Coltharp Douglas (Sold 29 110 shares of value $1 798 577 ), Douglas E. Coltharp (Option Excercise at a value of $359 153), Douglas E. Coltharp (Sold 17 895 shares of value $1 087 658 )
Mon, 27 Nov 2023 13:37 GMT Encompass Health names Spirit Airlines CEO Ted Christie to board- TipRanks. All rights reserved.
Fri, 27 Oct 2023 09:50 GMT Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC) and Sanofi (OtherSNYNF)- TipRanks. All rights reserved.
Wed, 23 Aug 2023 20:55 GMT Enhabit begins exploration of strategic alternatives- TipRanks. All rights reserved.
Wed, 02 Aug 2023 10:07 GMT Analysts Are Bullish on These Healthcare Stocks: Encompass Health (EHC), IQVIA Holdings (IQV)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.